Marinus Pharmaceuticals Faces Class Action Lawsuit for Securities Violations

Author:

The Schall Law Firm has recently filed a class action lawsuit against Marinus Pharmaceuticals, Inc. (“Marinus” or “the Company”) for alleged violations of securities laws. Investors who purchased the company’s securities between March 17, 2021 and May 7, 2024, have been encouraged to contact the law firm before August 5, 2024.

The lawsuit claims that Marinus Pharmaceuticals made false and misleading statements to the market. Specifically, the Company is accused of understating the risk of its RAISE trial failing and failing to inform investors of the potential consequences of this failure. As a result, the company’s public statements were alleged to be false and materially misleading throughout the class period.

Investors who suffered losses as a result of these alleged securities violations are urged to join the case in order to potentially recover their losses. The Schall Law Firm, a leading shareholder rights litigation firm, is representing investors from around the world who have been impacted by securities fraud.

It is important for shareholders to be aware that the class has not yet been certified, and until certification occurs, they will not be represented by an attorney. However, shareholders who choose to take no action may remain as absent class members in the lawsuit.

Marinus Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of innovative therapeutics to treat epilepsy and other neurological disorders. The outcome of this class action lawsuit may have significant implications for the company and its shareholders.

Investors who wish to participate in the lawsuit or seek further information are advised to contact the Schall Law Firm directly. The firm can be reached through their website or by phone, and initial consultations are provided free of charge.

Please note that this press release may be considered Attorney Advertising in some jurisdictions, in accordance with applicable law and rules of ethics.

Contact:

The Schall Law Firm
Brian Schall, Esq.
Website: www.schallfirm.com
Office: 310-301-3335
Email: [email protected]

SOURCE: The Schall Law Firm

Marinus Pharmaceuticals, Inc. is currently facing a class action lawsuit for alleged violations of securities laws. The lawsuit, filed by The Schall Law Firm, claims that the company made false and misleading statements to the market. Specifically, Marinus Pharmaceuticals is accused of downplaying the risks associated with its RAISE trial and failing to inform investors of the potential consequences if the trial were to fail. These alleged actions resulted in false and materially misleading public statements throughout the class period.

Investors who purchased Marinus Pharmaceuticals’ securities between March 17, 2021, and May 7, 2024, have been encouraged to contact The Schall Law Firm before August 5, 2024, in order to potentially recover their losses. It is important to note that the class has not yet been certified, so shareholders who choose not to take any action may remain as absent class members in the lawsuit.

Marinus Pharmaceuticals is a pharmaceutical company that focuses on developing and commercializing therapeutics for epilepsy and other neurological disorders. The outcome of this class action lawsuit could have significant implications for the company and its shareholders.

While the specific details and merits of the lawsuit are not discussed in the provided article, it is worth noting that class action lawsuits involving securities violations can have various outcomes. In some cases, settlements may be reached where the company agrees to compensate affected investors. However, there are instances where the lawsuits can result in substantial financial losses for the company or lead to reputational damage.

It is important for investors to gather more information about the case and consult with legal professionals to understand the potential risks and benefits of participating in the lawsuit. Investors who wish to participate or seek further information should contact The Schall Law Firm directly. Initial consultations are provided free of charge.

Please note that this is a press release, and in some jurisdictions, it may be considered Attorney Advertising in accordance with applicable law and rules of ethics.

For more information about the case or to contact The Schall Law Firm, visit their website: www.schallfirm.com.

Source: The Schall Law Firm